SymBio Pharmaceuticals Limited
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SYMQY research report →
Companywww.symbiopharma.com
SymBio Pharmaceuticals Limited engages in the research and development, manufacturing, and marketing of pharmaceutical drugs in the areas of oncology and hematology in Japan. It is involved in the development of Treakisym SyB L-0501, an anti-cancer agent, which is marketed for the treatment of non-Hodgkin's lymphoma, multiple myeloma, and chronic lymphocytic leukemia under the TREAKISYM name; and is in the Phase III clinical trial to treat relapsed/refractory diffuse large B-cell lymphoma. The company also engages in the development of SyB L-1701, a ready-to-dilute formulation; and SyB L-1702, a rapid infusion liquid formulation.
- CEO
- Fuminori Yoshida
- IPO
- 2016
- Employees
- 108
- HQ
- Tokyo, JP
Price Chart
Valuation
- Market Cap
- $26.38M
- P/E
- -0.95
- P/S
- 3.58
- P/B
- 23.97
- EV/EBITDA
- -0.65
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 71.86%
- Op Margin
- -439.49%
- Net Margin
- -458.55%
- ROE
- -424.34%
- ROIC
- -444.00%
Growth & Income
- Revenue
- $1.37B · -44.11%
- Net Income
- $-5,007,740,554 · -30.63%
- EPS
- $-99.73 · -18.64%
- Op Income
- $-4,655,968,416
- FCF YoY
- -38.52%
Performance & Tape
- 52W High
- $1.19
- 52W Low
- $0.56
- 50D MA
- $0.56
- 200D MA
- $0.72
- Beta
- 0.55
- Avg Volume
- 804.66
Get TickerSpark's AI analysis on SYMQY
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our SYMQY Coverage
We haven't published any research on SYMQY yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate SYMQY Report →